Skip to main content
Erschienen in: Clinical Rheumatology 12/2018

11.07.2018 | Brief Report

Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis

verfasst von: Abhishek Zanwar, Avinash Jain, Latika Gupta, Smirti Chaurasia, Sandeep Kumar, Durga Prasanna Misra, Ramnath Misra

Erschienen in: Clinical Rheumatology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Despite many studies focused on involvement of T cell in pathogenesis of Takayasu arteritis (TaK), very few have explored the role of B cells. Hence, we sought evidence of B cell involvement in a large cohort of TaK by measuring serum levels of B cell survival factors activation factor (BAFF) and A proliferation inducing ligand (APRIL). Serum BAFF and APRIL levels were measured by ELISA in 50 patients and 48 healthy individuals, and further assessed for correlation with outcome measures, such as Indian Takayasu Clinical Activity Score-ESR (ITAS-ESR) and Takayasu arteritis Damage score (TADS). Forty women and ten men of median age 26 (11–52) and disease duration of 3 years (0.1–22) were studied. Type V disease was the most common subset (n = 31), while type I, II, III, and IV was seen in ten, four, three, and two patients respectively. Serum APRIL levels were raised in patients as compared to healthy controls [2087.5 pg/ml (1480.0–2279.0) vs. 1288.64 pg/ml, (844.2–1632.9) p = 0.01]. Median serum APRIL level was also raised in patients with active disease (n = 24) as compared to inactive disease (n = 26) 2098.79 pg/ml, (1930.75–2768.75) vs. 1802.5 pg/ml, (1066.75–2098); p = 0.03). Serum BAFF levels were not raised in patients with TaK when compared to healthy Individuals. Neither BAFF, nor APRIL levels correlated with disease activity (ITAS-ESR) or TADS. Elevated APRIL levels in active TaK suggest probable role of B cells in pathogenesis.
Literatur
1.
Zurück zum Zitat Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn J-E, Benhamou Y, Chiche L, Koskas F, Cluzel P, Hachulla E, Messas E, Resche-Rigon M, Cacoub P, Mirault T, Saadoun D (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136(12):1114–1122CrossRef Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn J-E, Benhamou Y, Chiche L, Koskas F, Cluzel P, Hachulla E, Messas E, Resche-Rigon M, Cacoub P, Mirault T, Saadoun D (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136(12):1114–1122CrossRef
2.
Zurück zum Zitat Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann K-G, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71(1):75–79CrossRef Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann K-G, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71(1):75–79CrossRef
3.
Zurück zum Zitat Nishino Y, Tamai M, Kawakami A, Koga T, Makiyama J, Maeda Y et al (2010) Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol 28(1 Suppl 57):14–17PubMed Nishino Y, Tamai M, Kawakami A, Koga T, Makiyama J, Maeda Y et al (2010) Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol 28(1 Suppl 57):14–17PubMed
4.
Zurück zum Zitat Morais SA, Vilas-Boas A, Isenberg DA (2015) B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 7(4):122–151CrossRef Morais SA, Vilas-Boas A, Isenberg DA (2015) B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 7(4):122–151CrossRef
5.
Zurück zum Zitat Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190(3):291–292CrossRef Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190(3):291–292CrossRef
6.
Zurück zum Zitat Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L (2011) Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 53(1):174–180CrossRef Wang H, Ma J, Wu Q, Luo X, Chen Z, Kou L (2011) Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 53(1):174–180CrossRef
7.
Zurück zum Zitat Kluz J, Adamiec R (2004) Role of anti-endothelial cell antibodies (AECA) in the development of Takayasu’s arteritis. Pol Arch Med Wewn 111(2):237–242PubMed Kluz J, Adamiec R (2004) Role of anti-endothelial cell antibodies (AECA) in the development of Takayasu’s arteritis. Pol Arch Med Wewn 111(2):237–242PubMed
8.
Zurück zum Zitat Misra R, Aggarwal A, Chag M, Sinha N, Shrivastava S (1994) Raised anticardiolipin antibodies in Takayasu’s arteritis. Lancet Lond Engl 343(8913):1644–1645CrossRef Misra R, Aggarwal A, Chag M, Sinha N, Shrivastava S (1994) Raised anticardiolipin antibodies in Takayasu’s arteritis. Lancet Lond Engl 343(8913):1644–1645CrossRef
9.
Zurück zum Zitat Tripathy NK, Sinha N, Nityanand S (2003) Anti-annexin V antibodies in Takayasu’s arteritis: prevalence and relationship with disease activity. Clin Exp Immunol 134(2):360–364CrossRef Tripathy NK, Sinha N, Nityanand S (2003) Anti-annexin V antibodies in Takayasu’s arteritis: prevalence and relationship with disease activity. Clin Exp Immunol 134(2):360–364CrossRef
10.
Zurück zum Zitat Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134CrossRef Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134CrossRef
11.
Zurück zum Zitat Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA (2013) Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatol Oxf Engl 52(10):1795–1801CrossRef Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA (2013) Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatol Oxf Engl 52(10):1795–1801CrossRef
12.
Zurück zum Zitat Gupta L, Chaurasia S, Srivastava P, Dwivedi S, Lawrence A, Misra R (2018) Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults. Clin Rheumatol 37(5):1265–1271CrossRef Gupta L, Chaurasia S, Srivastava P, Dwivedi S, Lawrence A, Misra R (2018) Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults. Clin Rheumatol 37(5):1265–1271CrossRef
13.
Zurück zum Zitat Phatak S, Chaurasia S, Mishra SK, Gupta R, Agrawal V, Aggarwal A, Misra R (2017) Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 187(3):376–382CrossRef Phatak S, Chaurasia S, Mishra SK, Gupta R, Agrawal V, Aggarwal A, Misra R (2017) Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 187(3):376–382CrossRef
14.
Zurück zum Zitat Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54(1):192–201CrossRef Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54(1):192–201CrossRef
15.
Zurück zum Zitat Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F (1997) Clinical manifestations of Takayasu arteritis in India and Japan—new classification of angiographic findings. Angiology 48(5):369–379CrossRef Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F (1997) Clinical manifestations of Takayasu arteritis in India and Japan—new classification of angiographic findings. Angiology 48(5):369–379CrossRef
16.
Zurück zum Zitat Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77(3):348–354CrossRef Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77(3):348–354CrossRef
17.
Zurück zum Zitat Weidenbusch M, Römmele C, Schröttle A, Anders H-J (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28(1):106–111CrossRef Weidenbusch M, Römmele C, Schröttle A, Anders H-J (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28(1):106–111CrossRef
18.
Zurück zum Zitat Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581CrossRef Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581CrossRef
20.
Zurück zum Zitat Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48(4):982–992CrossRef Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48(4):982–992CrossRef
Metadaten
Titel
Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis
verfasst von
Abhishek Zanwar
Avinash Jain
Latika Gupta
Smirti Chaurasia
Sandeep Kumar
Durga Prasanna Misra
Ramnath Misra
Publikationsdatum
11.07.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 12/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4207-y

Weitere Artikel der Ausgabe 12/2018

Clinical Rheumatology 12/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.